Bernard Lehrhoff
Urology · Cranford, NJNPI 1336136282
Payments from drug & device makers
Across 147 payments — averaging $13.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$383
- Pfizer$331
- Halozyme Inc$239
- Ferring Pharmaceuticals Inc.$194
- Endo Pharmaceuticals Inc.$193
- Bayer$138
- plus $452 from 14 others
What the payments were for
- Food & beverage$1,91899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 32 | $383 |
| Pfizer | 28 | $331 |
| Halozyme Inc | 20 | $239 |
| Ferring Pharmaceuticals Inc. | 17 | $194 |
| Endo Pharmaceuticals Inc. | 14 | $193 |
| Bayer | 8 | $138 |
| Astellas Pharma US Inc | 7 | $96 |
| Myovant Sciences Inc. | 5 | $74 |
| Arteriocyte Medical Systems, Inc. | 1 | $62 |
| 180 Medical, Inc. | 2 | $36 |
| Boston Scientific | 2 | $34 |
| AbbVie | 2 | $26 |
| Myriad Genetic Laboratories, Inc. | 2 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Tempus AI, Inc | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Medtronic | 1 | $13 |
| Mission Pharmacal Company | 1 | $12 |
| Dentsply IH Inc. | 1 | $11 |
How this compares
$1,930 in reported general payments places this provider in the 45th percentile of 401 urology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 166 | $117,172 |
| GemtesaVibegron | 19 | $15,405 |
| Potassium Citrate ErPotassium Citrate | 45 | $8,576 |
| Tamsulosin Hcl | 471 | $7,873 |
| Finasteride | 287 | $4,831 |
| Silodosin | 28 | $2,854 |
| Solifenacin Succinate | 46 | $2,609 |
| Dutasteride | 51 | $1,886 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $1,387 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 46 | $1,001 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $800 |
| Desmopressin Acetate | 13 | $577 |
| Allopurinol | 20 | $316 |
| Oxybutynin Chloride | 13 | $194 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $96 | $117,172166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 401 urology providers in New Jersey.
Other urology in Cranford
- Neil ShermanCranford$404K
- Rupa PatelCranford$128K
- Mark MillerCranford$24K
- Benjamin FandCranford$21K
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.